PortfoliosLab logo
PortfoliosLab logo
Tools
Portfolios
Screeners
Discussions
TECH vs. MRNA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

TECH vs. MRNA

Last updated May 12, 2025

Compare and contrast key facts about Bio-Techne Corporation (TECH) and Moderna, Inc. (MRNA).

Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: TECH or MRNA.

Correlation

The correlation between TECH and MRNA is 0.80, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.

Performance

TECH vs. MRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Bio-Techne Corporation (TECH) and Moderna, Inc. (MRNA). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Daily Std Dev

TECH:

47.29%

MRNA:

97.14%

Max Drawdown

TECH:

-4.18%

MRNA:

-13.58%

Current Drawdown

TECH:

0.00%

MRNA:

-12.90%

Fundamentals

Market Cap

TECH:

$7.89B

MRNA:

$9.38B

EPS

TECH:

$0.83

MRNA:

-$8.73

PEG Ratio

TECH:

1.33

MRNA:

0.00

PS Ratio

TECH:

6.53

MRNA:

2.95

PB Ratio

TECH:

3.91

MRNA:

0.93

Total Revenue (TTM)

TECH:

$892.59M

MRNA:

$3.16B

Gross Profit (TTM)

TECH:

$581.78M

MRNA:

$1.66B

EBITDA (TTM)

TECH:

$245.55M

MRNA:

-$3.20B

Returns By Period

TECH

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

MRNA

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Risk-Adjusted Performance

TECH vs. MRNA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
TECH
The Risk-Adjusted Performance Rank of TECH is 99
Overall Rank
The Sharpe Ratio Rank of TECH is 55
Sharpe Ratio Rank
The Sortino Ratio Rank of TECH is 99
Sortino Ratio Rank
The Omega Ratio Rank of TECH is 1111
Omega Ratio Rank
The Calmar Ratio Rank of TECH is 1616
Calmar Ratio Rank
The Martin Ratio Rank of TECH is 22
Martin Ratio Rank
MRNA
The Risk-Adjusted Performance Rank of MRNA is 55
Overall Rank
The Sharpe Ratio Rank of MRNA is 22
Sharpe Ratio Rank
The Sortino Ratio Rank of MRNA is 11
Sortino Ratio Rank
The Omega Ratio Rank of MRNA is 22
Omega Ratio Rank
The Calmar Ratio Rank of MRNA is 44
Calmar Ratio Rank
The Martin Ratio Rank of MRNA is 1717
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

TECH vs. MRNA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Bio-Techne Corporation (TECH) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

No data
No data
No data
No data
No data

Loading data...

Dividends

TECH vs. MRNA - Dividend Comparison

TECH's dividend yield for the trailing twelve months is around 0.48%, while MRNA has not paid dividends to shareholders.

TTM20242023202220212020201920182017201620152014
TECH
Bio-Techne Corporation		0.48%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
MRNA
Moderna, Inc.		0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Drawdowns

TECH vs. MRNA - Drawdown Comparison

The maximum TECH drawdown since its inception was -4.18%, smaller than the maximum MRNA drawdown of -13.58%. Use the drawdown chart below to compare losses from any high point for TECH and MRNA. For additional features, visit the drawdowns tool.

Loading data...

Volatility

TECH vs. MRNA - Volatility Comparison

Loading data...

Financials

TECH vs. MRNA - Financials Comparison

This section allows you to compare key financial metrics between Bio-Techne Corporation and Moderna, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.

Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities

0.001.00B2.00B3.00B4.00B5.00B6.00B7.00B20212022202320242025
297.03M
107.00M
(TECH) Total Revenue
(MRNA) Total Revenue
Values in USD except per share items